Glycophos

Glycophos is a sterile solution for injection that contains the active ingredient sodium glycerophosphate pentahydrate. It is supplied in an unspecified strength and is marketed in the European Union as a prescription‑only electrolyte supplement used to replenish phosphate levels in the body.

Glycophos is indicated for clinical situations where phosphate replacement is required. It is commonly employed in the following contexts:

- Treatment of hypophosphatemia resulting from renal loss, malnutrition, or chronic alcoholism. - Prevention of phosphate depletion in patients receiving total parenteral nutrition. - Support of electrolyte balance during intensive care or major surgery. - Adjunct therapy for metabolic disorders that involve phosphate deficiency. - Management of phosphate loss associated with certain diuretic regimens.

Adverse reactions to Glycophos may vary in frequency and severity. Reported events include:

Common: - Mild injection site discomfort or erythema. - Transient nausea or vomiting. - Slight increase in serum sodium levels. - Temporary elevation of serum calcium. - Mild headache. - Low-grade fever.

Serious: - Hyperphosphatemia leading to calcium‑phosphate precipitation. - Severe hypernatremia causing neurological symptoms. - Allergic reactions such as urticaria or anaphylaxis. - Metabolic acidosis in susceptible individuals. - Cardiac arrhythmias secondary to electrolyte imbalance. - Acute kidney injury due to phosphate overload.

Before administering Glycophos, clinicians should consider several safety factors. Important precautions include:

- Assess baseline serum phosphate, calcium, and sodium levels to avoid over‑correction. - Use caution in patients with renal insufficiency or on dialysis. - Monitor for signs of fluid overload, especially in heart‑failure patients. - Adjust dose in individuals with severe electrolyte disturbances. - Avoid rapid infusion rates that may precipitate cardiovascular events. - Consider pregnancy status; data on fetal safety are limited. - Discontinue if an allergic reaction develops.

Glycophos may interact with other medications or therapies. Potential interactions are categorized as follows:

Avoid: - Concurrent use of high‑dose calcium supplements, which can increase the risk of calcium‑phosphate precipitation. - Co‑administration with other phosphate‑containing intravenous solutions without monitoring.

Use with caution: - Loop diuretics that promote electrolyte loss, requiring closer monitoring of phosphate and sodium. - ACE inhibitors or ARBs, which may affect renal handling of electrolytes. - Antacids containing aluminum or magnesium, which can bind phosphate. - Vitamin D analogues, as they influence calcium‑phosphate metabolism. - Blood transfusions, which may alter phosphate balance.